Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-nave adults with HIV infection in the United States

Value in Health

Volumn 14, Issue 5, 2011, Pages 657-664

  Brogan, Anita J ^a   Talbird, Sandra E ^a   Cohen, Calvin ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b Boston Community Research Initiative of New England   (United States)

Author keywords

AIDS; cost effectiveness analysis; drug combinations; Markov model

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; CD4 ANTIGEN; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; TENOFOVIR;

ACUTE HEART INFARCTION; ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL COUNT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; FEMALE; HEALTH STATUS; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIPOATROPHY; MALE; MORTALITY; NUCLEOTIDE SEQUENCE; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT OUTCOME; UNITED STATES;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS AS TOPIC; COST SAVINGS; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG COSTS; FEMALE; HEALTH SERVICES RESEARCH; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MARKOV CHAINS; MODELS, ECONOMIC; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PHOSPHONIC ACIDS; QUALITY-ADJUSTED LIFE YEARS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD; ZIDOVUDINE;

EID: 80052474630     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.01.009     Document Type: Article

References (50)

1. A. Mocroft, B. Ledergerber, and C. Katlama Decline in the AIDS and death rates in the EuroSIDA study: an observational study Lancet 362 2003 22 29 (Pubitemid 36835816)
2. N.F. Crum, R.H. Riffenburgh, and S. Wegner Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras J Acquir Immune Defic Syndr 41 2006 194 200
3. F.J. Palella Jr., R.K. Baker, and A.C. Moorman Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study J Acquir Immune Defic Syndr 43 2006 27 34 (Pubitemid 44306484)
4. N. Lohse, A.B. Hansen, and G. Pedersen Survival of persons with and without HIV infection in Denmark, 19952005 Ann Intern Med 146 2007 87 95 (Pubitemid 351640011)
5. H.B. Krentz, G. Kliewer, and M.J. Gill Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003 HIV Med 6 2005 99 106 (Pubitemid 40425973)
6. Antiretroviral Therapy Cohort Collaboration Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies Lancet 372 2008 293 299
7. D.R. Holtgrave, and S.D. Pinkerton Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs J Acquir Immune Defic Syndr Hum Retrovirol 16 1997 54 62
8. B.R. Schackman, K.A. Gebo, and R.P. Walensky The lifetime cost of current human immunodeficiency virus care in the United States Med Care 44 2006 990 997 (Pubitemid 44674030)
9. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents US Department of Health and Human Services; December 1, 2009 http://aidsinfo.nih. gov/contentfiles/AdultandAdolescentGL.pdf [Accessed December 29, 2009]
10. A.L. Gifford, J.E. Bormann, and M.J. Shively Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens J Acquir Immune Defic Syndr 23 2000 386 395 (Pubitemid 30431595)
11. J. Jordan, J. Tolson, and T. Delea Impact of fixed-dose combination zidovudine/lamivudine on adherence to antiretroviral therapy: a retrospective claims-based cohort study [Poster] Presented at: 6th International Congress on Drug Therapy in HIV Infection Glasgow, UK November 1721, 2002
12. S.D. Portsmouth, J. Osorio, and K. McCormick Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules HIV Med 6 2005 185 190 (Pubitemid 40740335)
13. Antiretroviral Therapy Cohort Collaboration Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies J Infect Dis 194 2006 612 622
14. J.A. Bartlett, S.S. Chen, and J.B. Quinn Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview HIV Clin Trials 8 2007 221 226 (Pubitemid 47327459)
15. J.E. Gallant, E. DeJesus, and J.R. Arribas Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV N Engl J Med 354 2006 251 260 (Pubitemid 43113030)
16. A.L. Pozniak, J.E. Gallant, and E. DeJesus Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes a 96-week analysis J Acquir Immune Defic Syndr 43 2006 535 540 (Pubitemid 44885619)
17. J.R. Arribas, A.L. Pozniak, and J.E. Gallant Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-nave patients: 144-week analysis J Acquir Immune Defic Syndr 47 2008 74 78 (Pubitemid 351619372)
18. P.E. Sax, C. Tierney, and A.C. Collier Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy N Engl J Med 361 2009 2230 2240
19. E. Daar, C. Tierney, and M. Fischl ACTG 5202: final results of ABC/3TC or TDF/FTC with either EFV or ATV/r in treatment-nave HIV-infected patients [Podium Presentation] Presented at: 17th Conference on Retroviruses & Opportunistic Infections San Francisco, CA February 16-19, 2010
20. H.J. Stellbrink, G. Moyle, and C. Orkin Assessment of safety and efficacy of abacavir/lamivudine and tenofovir/emtricitabine in treatment-nave HIV-1 infected subjects ASSERT: 48-week results [Abstract] Presented at: 12th European AIDS Conference Cologne, Germany November 11-14, 2009
21. F.A. Post, G.J. Moyle, and H.J. Stellbrink Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study J Acquir Immune Defic Syndr 55 2010 49 57
22. A. Hill, and W. Sawyer Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients HIV Med 10 2009 527 535
23. S.A. Riddler, R. Haubrich, and A.G. DiRienzo Class-sparing regimens for initial treatment of HIV-1 infection N Engl J Med 358 2008 2095 2106 (Pubitemid 351679596)
24. R.H. Haubrich, S.A. Riddler, and A.G. DiRienzo Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment AIDS 23 2009 1109 1118
25. J. Young, H.C. Bucher, and H.F. Guenthard Virologic and immunologic responses to efavirenz or boosted lopinavir as first therapy for patients with HIV in the Swiss HIV Cohort Study [Poster] Presented at: 5th International AIDS Society Conference on HIV Pathogenesis and Treatment Cape Town, South Africa July 19-22, 2009
26. 3 in Mexico J Acquir Immune Defic Syndr 53 2010 582 588
27. E.J. Beck, S. Mandalia, and M. Youle Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (19962002) Int J STD AIDS 19 2008 297 304 (Pubitemid 351748269)
28. M.R. Gold, J.E. Siegel, L.B. Russell, and M.C. Weinstein Cost-effectiveness in Health and Medicine 1996 Oxford University Press New York
29. E. DeJesus, G. Herrera, and E. Teofilo Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults Clin Infect Dis 39 2004 1038 1046 (Pubitemid 39313463)
30. A.N. Phillips, B. Ledergerber, and J.R. Bogner Rate of change in CD4 counts in patients with stable HIV viremia [Poster] Presented at: 9th International Congress on Drug Therapy in HIV Infection Glasgow, UK November 9-13, 2008
31. Y. Yazdanpanah, C. Fagard, and D. Descamps High rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: results of the ANRS 139 TRIO trial [Podium Presentation] Presented at: 17th International AIDS Conference Mexico City, Mexico August 38, 2008
32. C. Fagard, D. Descamps, and V. Dubar Efficacy and safety of raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: 48-week results from the ANRS 139 TRIO trial [Abstract] Presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention Cape Town, South Africa July 1922, 2009
33. B. Ledergerber, J.D. Lundgren, and A.S. Walker Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes Lancet 364 2004 51 62
34. Version 61127 Red Book for Windows Volume 53 2009 Thomson PDR Montvale, NJ
35. K. Gebo, J. Fleishman, and R. Conviser Contemporary costs of HIV health care in the HAART era [Poster] Presented at: 13th Conference on Retroviruses and Opportunistic Infections Denver, CO February 58, 2006
36. The Essential RBRVS 2009 A Comprehensive Listing of RBRVS Values for CPT and HCPCS Codes 2009 Ingenix, Inc Salt Lake City, Utah
37. Bureau of Labor Statistics Medical care component of consumer price indexall urban consumers (current series), not seasonally adjusted US Department of Labor; June 2009 http://www.bls.gov/CPI/ [Accessed August 31, 2009]
38. B.R. Schackman, S.J. Goldie, and K.A. Freedberg Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS Med Decis Making 22 2002 27 38 (Pubitemid 34087688)
39. M. Heron, D.L. Hoyert, and S.L. Murphy Deaths: final data for 2006 Natl Vital Stat Rep 57 2009 1 134
40. 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population J Acquir Immune Defic Syndr 46 2007 72 77 (Pubitemid 47514615)
41. S.M. Curkendall, Q.V. Doan, and F. Everhard Direct costs of anemia among patients treated with zidovudine [Poster] Presented at: 12th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research Arlington, VA May 1923, 2007
42. L.A. Lenert, M. Feddersen, A. Sturley, and D. Lee Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection Am J Med 113 2002 229 232 (Pubitemid 35245632)
43. J. Lundgren, P. Reiss, and S. Worm Risk of myocardial infarction with exposure to specific ARV from the PI, NNRTI, and NRTI drug classes: the D:A:D study [Abstract] Presented at: 16th Conference on Retroviruses and Opportunistic Infections Montreal, Canada February 8-11, 2009
44. M. Pignone, S. Earnshaw, M.J. Pletcher, and J.A. Tice Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis Arch Intern Med 167 2007 290 295
45. J. Tsevat, L. Goldman, and J.R. Soukup Stability of time-tradeoff utilities in survivors of myocardial infarction Med Decis Making 13 1993 161 165 (Pubitemid 23113453)
46. B.R. Schackman, C.A. Scott, and R.P. Walensky The cost-effectiveness of HLA-B (*)5701 genetic screening to guide initial antiretroviral therapy for HIV AIDS 22 2008 2025 2033
47. V.D. Lima, R.S. Hogg, and P.R. Harrigan Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy AIDS 21 2007 685 692 (Pubitemid 46568625)
48. E. Lloyd-Smith, E. Brodkin, and E. Wood Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia AIDS 20 2006 445 450
49. J. Munakata, J.S. Benner, and S. Becker Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus Med Care 44 2006 893 899 (Pubitemid 44454565)
50. R.S. Braithwaite, A.C. Justice, and C.C. Chang Estimating the proportion of patients infected with HIV who will die of comorbid diseases Am J Med 118 2005 890 898 (Pubitemid 41097468)